scholarly journals Faster Aspart: a fast-acting insulin analog for an optimal glycemic control

2021 ◽  
Vol 24 (3) ◽  
pp. 196
Author(s):  
Irace, C.
Keyword(s):  
Insulin Aspart ◽  
Therapeutic Option ◽  
Glycosylated Hemoglobin ◽  
Insulin Regimen ◽  
Chronic Complications ◽  
Acting Insulin ◽  
Clinical Benefits ◽  
Bolus Insulin ◽  
Basal Bolus ◽  
Fast Acting

The basal-bolus insulin regimen in the management of diabetes is essential to achieve the recommended glycosylated hemoglobin (HbA1c) to reduce the incidence or the progression of chronic complications. HbA1c is influenced by either fasting plasma glucose and post-prandial hyperglycemia. Faster Aspart is an insulin Aspart with two additional excipients, L-arginine and niacinamide, which provide a faster subcutaneous absorption, the earlier onset of appearance, and consequently the optimization of post-prandial glucose control. Faster Aspart has been widely investigated in the ‘‘onset’’ clinical trials, which show better post-prandial glycemic excursions and noninferiority compared to insulin Aspart with HbA1c reduction. Clinical evidence demonstrates that faster Aspart is a therapeutic option able to provide clinical benefits over the current rapid-acting insulin analogs in terms of improved meal-related glycaemic control in subjects with diabetes. KEY WORDS post-prandial hyperglycemia; cardiovascular disease; insulin treatment; faster-acting insulin; faster aspart.

Biphasic Insulin Aspart Given Thrice Daily is as Efficacious as a Basal-Bolus Insulin Regimen with Four Daily Injections

2006 ◽  
Vol 114 (09) ◽  
pp. 511-519 ◽  
Author(s):  
R. Ligthelm ◽  
U. Mouritzen ◽  
H. Lynggaard ◽  
M. Landin-Olsson ◽  
C. Fox ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Insulin Regimen ◽  
Biphasic Insulin Aspart ◽  
Biphasic Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

1034-P: Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1034-P
Author(s):  
EDWARD FRANEK ◽  
MAGNUS EKELUND ◽  
ÓLÖF THÓRISDÓTTIR ◽  
HAK CHUL JANG ◽  
KATARINA LALIC ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Efficacy And Safety ◽  
Baseline Hba1c ◽  
Acting Insulin ◽  
Basal Bolus ◽  
Fast Acting

1037-P: Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1037-P
Author(s):  
WENDY LANE ◽  
MAGNUS EKELUND ◽  
ÓLÖF THÓRISDÓTTIR ◽  
ESTEBAN JÓDAR ◽  
ALEJANDRA OVIEDO ◽  
...  
Keyword(s):  
Insulin Aspart ◽  
Efficacy And Safety ◽  
Insulin Requirements ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

2019 ◽  
Vol 7 (1) ◽  
pp. e000679 ◽  
Author(s):  
Jochen Seufert ◽  
Anja Borck ◽  
Peter Bramlage
Keyword(s):  
Basal Insulin ◽  
Fixed Ratio ◽  
Severe Hypoglycemia ◽  
Insulin Regimen ◽  
Premixed Insulin ◽  
Minimal Impact ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin ◽  
Basal Bolus

We summarize here clinical and trial data on a once-daily administration of a single bolus to the meal with the largest expected postprandial glucose excursion (basal-plus), and comment on its clinical utility in the treatment of type 2 diabetes. A PubMed search of data published until September 2018 was taken into consideration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eighteen reports representing 15 studies were identified (age: 18–80 years; 50–890 patients; follow-up: 8 days to 60 weeks). Data suggest basal-plus is efficacious for improving glycemic control, with a low incidence of (severe) hypoglycemia and minor increases in bodyweight. The timing of short-acting insulin administration and use of different monitoring/titration approaches appear to have minimal impact. When compared with premixed insulin, basal-plus results in largely comparable outcomes. Compared with basal-bolus, it may result in non-inferior glycemic improvements with less weight gain, less hypoglycemia and fewer daily injections. A basal insulin/glucagon-like peptide-1 receptor agonist fixed ratio combination may offer several advantages over the basal-plus regimen, at the cost of gastrointestinal side effects. We conclude that the stepwise introduction of short-acting insulin via the basal-plus strategy represents a viable alternative to a full basal-bolus regimen and may help to overcome barriers associated with multiple injections and anticipated complexity of the insulin regimen.

Sign in / Sign up

Export Citation Format

Share Document